News | August 01, 2024
Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
